HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jon D Morrow Selected Research

fesoterodine

11/2012Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
11/2011Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
2/2011Early onset of fesoterodine efficacy in subjects with overactive bladder.
2/2011Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.
4/2010Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
1/2010Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
1/2010Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder.
7/2009Efficacy and tolerability of fesoterodine in women with overactive bladder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jon D Morrow Research Topics

Disease

12Overactive Urinary Bladder (Overactive Bladder)
11/2012 - 11/2008
7Urinary Incontinence
11/2012 - 11/2008
2Constipation
01/2010 - 01/2010
1COVID-19
12/2022

Drug/Important Bio-Agent (IBA)

8fesoterodineFDA Link
11/2012 - 07/2009
6Tolterodine Tartrate (Detrol)FDA Link
11/2012 - 11/2008
2Muscarinic AntagonistsIBA
05/2012 - 04/2010
1Indicators and Reagents (Reagents)IBA
12/2022
1salicylhydroxamic acid (SHAM)IBA
05/2012